MCID: CYT008
MIFTS: 62

Cytomegalovirus Infection

Categories: Blood diseases, Immune diseases

Aliases & Classifications for Cytomegalovirus Infection

MalaCards integrated aliases for Cytomegalovirus Infection:

Name: Cytomegalovirus Infection 55 3 17
Cytomegalovirus Infections 44 74

Classifications:



External Ids:

UMLS 74 C0010823

Summaries for Cytomegalovirus Infection

NINDS : 55 Cytomegalovirus (CMV) is a virus found throughout the world that infects between 50 to 80 percent of all adults in the United States by the age of 40.  CMV is in the same family of viruses that causes cold sores (herpes simplex virus), infectious mononucleosis (Epstein-Barr virus), and chickenpox/shingles (varicella zoster virus).    Most people who acquire CVM as children or adults display no signs of illness or have mild symptoms such as fever, fatigue, or tender lymph nodes.  People with a compromised immune system may have more severe forms of infection involving the nervous system. A hallmark of CMV infection is that the virus cycles through periods of dormancy and active infection during the life of the individual  Infected persons of any age periodically shed the virus in their body fluids, such as saliva, urine, blood, tears, semen, or breast milk.  CMV is most commonly transmitted when infected body fluids come in contact with the mucous membranes of an uninfected person, but the virus can also pass from mother to fetus during pregnancy.  

MalaCards based summary : Cytomegalovirus Infection, also known as cytomegalovirus infections, is related to congenital cytomegalovirus and colitis, and has symptoms including fever and pruritus. An important gene associated with Cytomegalovirus Infection is RAG1 (Recombination Activating 1), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Mycophenolic acid and Prednisone have been mentioned in the context of this disorder. Affiliated tissues include t cells, kidney and liver, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

MedlinePlus : 44 Cytomegalovirus (CMV) is a virus found around the world. It is related to the viruses that cause chickenpox and infectious mononucleosis (mono). Between 50 percent and 80 percent of adults in the United States have had a CMV infection by age 40. Once CMV is in a person's body, it stays there for life. CMV is spread through close contact with body fluids. Most people with CMV don't get sick and don't know that they've been infected. But infection with the virus can be serious in babies and people with weak immune systems. If a woman gets CMV when she is pregnant, she can pass it on to her baby. Usually the babies do not have health problems. But some babies can develop lifelong disabilities. A blood test can tell whether a person has ever been infected with CMV. Most people with CMV don't need treatment. If you have a weakened immune system, your doctor may prescribe antiviral medicine. Good hygiene, including proper hand washing, may help prevent infections. Centers for Disease Control and Prevention

CDC : 3 Cytomegalovirus (pronounced sy-toe-MEG-a-low-vy-rus), or CMV, is a common virus that infects people of all ages. Over half of adults by age 40 have been infected with CMV. Once CMV is in a person’s body, it stays there for life and can reactivate. Most people infected with CMV show no signs or symptoms. However, CMV infection can cause serious health problems for people with weakened immune systems and for unborn babies (congenital CMV).

Related Diseases for Cytomegalovirus Infection

Diseases related to Cytomegalovirus Infection via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 656)
# Related Disease Score Top Affiliating Genes
1 congenital cytomegalovirus 33.5 CCL2 IL1B TNF
2 colitis 31.3 CXCL8 IL1B IL6 TNF
3 inflammatory bowel disease 31.1 CXCL8 IL1B IL6 TNF
4 ulcerative colitis 31.0 CXCL8 IL1B IL6 TNF
5 hematopoietic stem cell transplantation 30.9 HLA-A HLA-B HLA-E IL6 TNF
6 rubella 30.8 HLA-A HLA-B TNF
7 bronchiolitis obliterans 30.8 CXCL8 IL6 TNF
8 toxoplasmosis 30.8 IL1B IL6 TNF
9 leukomalacia 30.6 IL6 TNF
10 chlamydia 30.5 CXCL8 IL1B IL6 TNF
11 crohn's colitis 30.5 CXCL8 IL1B TNF
12 acquired immunodeficiency syndrome 30.4 B2M CCL3 HLA-B IL1B IL6 TNF
13 arteries, anomalies of 30.4 CCL2 IL1B IL6 TNF
14 kawasaki disease 30.4 CCL2 IL6 TNF
15 cerebral palsy 30.4 IL1B IL6 TNF
16 perinatal necrotizing enterocolitis 30.4 CXCL8 IL1B IL6 TNF
17 hemophagocytic lymphohistiocytosis 30.4 B2M CXCL8 FAS TNF
18 common variable immunodeficiency 30.3 FAS IL6 NFKB1 RAG1 TNF
19 autoimmune disease 30.3 FAS IL1B IL6 TNF
20 graft-versus-host disease 30.3 FAS HLA-A HLA-B IL1B IL6 TNF
21 myocarditis 30.3 HLA-B IL6 TNF
22 acute respiratory distress syndrome 30.3 CXCL8 IL1B IL6 TNF
23 cytomegalovirus retinitis 30.3 HLA-A HLA-B TNF
24 bronchiolitis 30.3 CCL3 CCL5 CXCL8 IL6 TNF
25 pneumonia 30.2 CCL2 CCL3 CCL5 CXCL8 IL1B IL6
26 arthritis 30.2 CCL2 CXCL8 IL1B IL6 TNF
27 lyme disease 30.2 IL1B IL6 TNF
28 duodenal ulcer 30.1 CXCL8 IL1B TNF
29 neuritis 30.1 CCL2 CCL5 IL1B TNF
30 gastroenteritis 30.1 CXCL8 IL1B IL6 TNF
31 spondylitis 30.1 HLA-B IL6 TNF
32 cholangitis 30.1 HLA-B IL6 TNF
33 esophagitis 30.1 CXCL8 IL1B IL6
34 monocytic leukemia 30.1 CXCL8 IL1B IL6 TNF
35 uveitis 30.1 CCL2 HLA-B TNF
36 human immunodeficiency virus infectious disease 30.1 B2M CCL3 CCL5 IL6 TNF
37 pericarditis 30.1 IL1B IL6 TNF TNFRSF1A
38 central nervous system vasculitis 30.0 IL1B IL6 TNF
39 haemophilus influenzae 30.0 CXCL8 IL1B TNF
40 systemic lupus erythematosus 30.0 CCL2 CCL5 FAS IL1B IL6 TNF
41 transverse myelitis 30.0 CXCL8 IL6 TNF
42 bacterial infectious disease 30.0 CCL2 CXCL8 IL1B IL6 TNF
43 endometritis 30.0 IL1B IL6 TNF
44 human herpesvirus 8 30.0 HLA-A HLA-B IL6
45 adult-onset still's disease 29.9 IL1B IL6 TNF TNFRSF1A
46 idiopathic neutropenia 29.9 CCL5 IL1B IL6 TNF
47 myeloma, multiple 29.9 B2M CCL3 CXCL8 IL6 TNF
48 major depressive disorder 29.9 CREB1 IL1B IL6 TNF
49 cystitis 29.9 CCL2 CXCL8 IL6 TNF
50 bacterial vaginosis 29.9 CXCL8 IL1B IL6 TNF

Comorbidity relations with Cytomegalovirus Infection via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Heart Disease

Graphical network of the top 20 diseases related to Cytomegalovirus Infection:



Diseases related to Cytomegalovirus Infection

Symptoms & Phenotypes for Cytomegalovirus Infection

UMLS symptoms related to Cytomegalovirus Infection:


fever, pruritus

GenomeRNAi Phenotypes related to Cytomegalovirus Infection according to GeneCards Suite gene sharing:

27 (show all 25)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-103 10.82 HLA-A HLA-B HLA-G
2 Increased shRNA abundance (Z-score > 2) GR00366-A-110 10.82 HLA-A HLA-B HLA-G
3 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.82 HLA-E
4 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10.82 HLA-A HLA-B HLA-G EGFR
5 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.82 EGFR
6 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.82 HLA-E
7 Increased shRNA abundance (Z-score > 2) GR00366-A-156 10.82 HLA-A HLA-B HLA-G
8 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.82 HLA-E
9 Increased shRNA abundance (Z-score > 2) GR00366-A-178 10.82 HLA-A HLA-B HLA-G
10 Increased shRNA abundance (Z-score > 2) GR00366-A-186 10.82 HLA-E
11 Increased shRNA abundance (Z-score > 2) GR00366-A-19 10.82 HLA-A HLA-B HLA-G
12 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.82 EGFR
13 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.82 EGFR
14 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.82 EGFR
15 Increased shRNA abundance (Z-score > 2) GR00366-A-31 10.82 HLA-A HLA-B HLA-G HLA-E
16 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.82 EGFR
17 Increased shRNA abundance (Z-score > 2) GR00366-A-7 10.82 HLA-A HLA-B HLA-G
18 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10.82 HLA-A HLA-B HLA-G
19 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.82 EGFR
20 Decreased viability with paclitaxel GR00179-A-1 10.1 EGFR MTOR SP1
21 Decreased viability with paclitaxel GR00179-A-2 10.1 MTOR
22 Decreased viability with paclitaxel GR00179-A-3 10.1 EGFR MTOR SP1
23 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.77 CXCL8 FAS IL1B NFKB1 SP1 TNF
24 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.77 CXCL8 FAS IL1B NFKB1 SP1 TNF
25 Reduced mammosphere formation GR00396-S 9.5 CCL2 CCL3 CXCL8 EGFR FAS HLA-E

MGI Mouse Phenotypes related to Cytomegalovirus Infection:

47 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.28 B2M CREB1 EGFR FAS IL1B IL6
2 hematopoietic system MP:0005397 10.27 B2M CCL5 EGFR FAS HLA-G IL1B
3 growth/size/body region MP:0005378 10.26 B2M CREB1 EGFR FAS IL1B IL6
4 homeostasis/metabolism MP:0005376 10.25 B2M CREB1 EGFR FAS HLA-G IL1B
5 immune system MP:0005387 10.22 B2M CCL2 CCL5 EGFR FAS HLA-G
6 endocrine/exocrine gland MP:0005379 10.19 B2M CREB1 EGFR FAS IL6 MTOR
7 digestive/alimentary MP:0005381 10.11 B2M EGFR FAS IL6 NFKB1 RAG1
8 craniofacial MP:0005382 10.07 EGFR FAS IL1B NFKB1 SP1 TNF
9 integument MP:0010771 10.07 B2M EGFR FAS IL1B IL6 NFKB1
10 liver/biliary system MP:0005370 9.97 B2M EGFR FAS IL6 NFKB1 RAG1
11 nervous system MP:0003631 9.9 B2M CREB1 EGFR FAS IL1B IL6
12 neoplasm MP:0002006 9.86 B2M EGFR FAS IL1B IL6 RAG1
13 respiratory system MP:0005388 9.65 CREB1 EGFR FAS IL6 MTOR NFKB1
14 skeleton MP:0005390 9.36 CREB1 EGFR FAS IL1B IL6 MTOR

Drugs & Therapeutics for Cytomegalovirus Infection

Drugs for Cytomegalovirus Infection (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 277)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mycophenolic acid Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 24280-93-1 446541
2
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 53-03-2 5865
3
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 22916-47-8 4189
4
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 46835353 5284616 6436030
5
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 104987-11-3 6473866 445643 439492
6
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 70789204 6442177
7
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
8
Acyclovir Approved Phase 4,Phase 3,Phase 2,Not Applicable 59277-89-3 2022
9
Ganciclovir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 82410-32-0 3454
10
Valganciclovir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 175865-60-8 64147
11
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2921-57-5
12
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
13
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
14
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 302-25-0
15
Foscarnet Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 4428-95-9, 63585-09-1 3415
16
Cidofovir Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 113852-37-2 60613
17
Basiliximab Approved, Investigational Phase 4,Not Applicable 179045-86-4, 152923-56-3
18
Pancrelipase Approved, Investigational Phase 4,Not Applicable 53608-75-6
19
Formaldehyde Approved, Vet_approved Phase 4 50-00-0 712
20
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
21
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
22
tannic acid Approved Phase 4 1401-55-4
23
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
24
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9 24083
25
Infliximab Approved Phase 4 170277-31-3
26
Probenecid Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 57-66-9 4911
27
Azathioprine Approved Phase 4 446-86-6 2265
28
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
29
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
30
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
31
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
32
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
33
Prednisolone hemisuccinate Experimental Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2920-86-7
34
Phosphonoacetic Acid Experimental Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 4408-78-0 546
35 Triamcinolone hexacetonide Phase 4
36 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Not Applicable
37 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2
38 Hormones Phase 4,Phase 3,Phase 2
39 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2
42 Hormone Antagonists Phase 4,Phase 3,Phase 2
43 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Not Applicable
45 Triamcinolone diacetate Phase 4
46 Antitubercular Agents Phase 4,Phase 3,Phase 2,Not Applicable
47 Antifungal Agents Phase 4,Phase 3,Phase 2,Not Applicable
48 triamcinolone acetonide Phase 4
49 Calcineurin Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 glucocorticoids Phase 4,Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 388)
# Name Status NCT ID Phase Drugs
1 Evaluation of Early Use of Everolimus (EVE) on Cytomegalovirus (CMV) Infection in Renal Transplant Recipients Unknown status NCT01927588 Phase 4 Everolimus+Tacrolimus+Prednisone;Mycophenolate+Tacrolimus+Prednisone
2 PTH - Preemptive Treatment for Herpesviridae Unknown status NCT02152358 Phase 4 Aciclovir;Ganciclovir;Placebo
3 Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for Cytomegalovirus Infection Completed NCT01509404 Phase 4 Valganciclovir;Valganciclovir
4 Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporine Versus an Immunosuppressive Regimen With Mycophenolic Acid and Standard Dose of Cyclosporine A Completed NCT02328963 Phase 4 Everolimus;mycophenolic acid
5 Valganciclovir for Treatment of Cytomegalovirus Infection in Solid Organ Transplant Patients Completed NCT00730769 Phase 4 Single arm (ganciclovir and valganciclovir)
6 The Influence of Chronic CMV Infection on Influenza Vaccine Responses Completed NCT02134184 Phase 4
7 Prospective, Randomized Study for Predicting Human Cytomegalovirus (hCMV) Infection Based on Baseline hCMV Specific T-cell Response in Kidney Transplant Completed NCT02550639 Phase 4
8 Sirolimus Associated With Tacrolimus at Low Doses in Elderly Kidney Transplant Patients Completed NCT02683291 Phase 4 sirolimus;tacrolimus;mycophenolate;Prednisone;Basiliximab;Thymoglobulin
9 Determining a Viral Load Threshold for Treating Cytomegalovirus (CMV) Completed NCT00947141 Phase 4 ganciclovir (start when CMV PCR >200copies / ml x2);Stop treatment when 2 levels CMV PCR <3,000 copies / ml
10 A Study of Oral Valcyte (Valganciclovir) in Pediatric Kidney Transplant Recipients Completed NCT01376804 Phase 4 valganciclovir [Valcyte]
11 Valganciclovir to Prevent Cytomegalovirus Infection in Kidney and Kidney/Pancreas Transplant Recipients Completed NCT00034385 Phase 4 Valganciclovir
12 CMV Antiviral Prevention Strategies in D+R-Liver Transplants ("CAPSIL") Completed NCT01552369 Phase 4 Valganciclovir
13 Influence of Persistent CMV-infection on Immune Senescence Completed NCT00461695 Phase 4
14 A Study on Spermatogenesis in Male Renal Transplant Recipients Receiving Valganciclovir (Valcyte®) Versus Untreated Matched Controls Completed NCT01663740 Phase 4 Valganciclovir
15 Prophylaxis With Ganciclovir Improves Graft Survival in Renal Allograft Recipients Completed NCT00373165 Phase 4 Ganciclovir
16 VICTOR Study - A Study of Valcyte (Valganciclovir po) Compared to Ganciclovir iv in Patients With Cytomegalovirus (CMV) Disease Who Are Solid Organ Transplant Recipients Completed NCT00431353 Phase 4 Ganciclovir;valganciclovir [Valcyte]
17 Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium Mycophenolate Completed NCT01354301 Phase 4 Thymoglobulin;Everolimus;Basiliximabe;mycophenolate sodium;Tacrolimus;Tacrolimus;Tacrolimus
18 Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant Completed NCT02084446 Phase 4 Everolimus;Very Low Tacrolimus;Low Tacrolimus;Steroids;Thymoglobulin;Sodium Mycophenolate
19 Valganciclovir to Reduce T Cell Activation in HIV Infection Completed NCT00264290 Phase 4 Valganciclovir;Placebo
20 Safety and Efficacy of Intravenous Magnesium Sulfate in Modulating Changes in Symptoms and Divalent Cation Levels Associated With Foscavir Therapy: A Phase IV Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Pilot Study Completed NCT00002146 Phase 4 Magnesium sulfate;Foscarnet sodium
21 Pharmacokinetics of Cidofovir During Continuous Venovenous Hemofiltration Completed NCT01866397 Phase 4
22 Individualization of Ganciclovir and Valganciclovir Doses Using Bayesian Prediction in Renal Transplant Patients. Completed NCT01446445 Phase 4 Ganciclovir/ Valganciclovir according to SPC;Ganciclovir/ Valganciclovir according to PK model
23 Study Comparing Cyclosporine With Infliximab in Steroid-refractory Severe Attacks of Ulcerative Colitis Completed NCT00542152 Phase 4 CYCLOSPORINE VS INFLIXIMAB
24 Safety Outcomes of Lower Immunosuppression Versus Traditional Immunosuppression in Heart Transplant Recipients Completed NCT00299221 Phase 4 Tacrolimus;combination therapy
25 Everolimus in de Novo Heart Transplant Recipients Completed NCT01017029 Phase 4 Everolimus;Mycophenolate mofetil + Everolimus
26 A Multicenter Study of Oral Versus Intravenous Hydration in AIDS Patients With CMV Retinitis Treated With Foscavir (Foscarnet Sodium) Completed NCT00002125 Phase 4 Foscarnet sodium
27 In Utero Treatment of Cytomegalovirus congénitale Infection With Valacyclovir Completed NCT01651585 Phase 4 Valacyclovir arrow
28 Efficacy and Safety of the Switch From Sirolimus to Everolimus in Stable Maintenance Renal Transplant Patients Receiving a Calcineurin Inhibitor Free Regimen Completed NCT00170820 Phase 4 Everolimus
29 Individually Adapted Immunosuppression in de Novo Renal Transplantation Based on Immune Function Monitoring: a Prospective Randomised Study Completed NCT00895206 Phase 4 individual adapted immunosuppression;golden standard therapy
30 Comparison of Two Drugs, Cidofovir and Ganciclovir, in Treating Patients With AIDS Who Have CMV Retinitis Completed NCT00000894 Phase 4 Cidofovir;Probenecid;Ganciclovir
31 Conversion to Sirolimus: Effects in Cytomegalovirus Infection Recurrence Recruiting NCT02671318 Phase 4 Drug conversion to sirolimus;Maintenance of the current regimen
32 CMV-CTL for the Treatment of CMV Infection After HSCT Recruiting NCT03004261 Phase 4 Foscarnet;Ganciclovir
33 Comparison of the Efficacy and Safety of Sirolimus Versus Everolimus Versus Mycophenolate in Kidney Transplantation Recruiting NCT03468478 Phase 4 Sirolimus;Everolimus;Mycophenolic acid
34 Topical 2% Ganciclovir Eye Drop for CMV Anterior Uveitis / Endotheliitis Recruiting NCT02943057 Phase 4 2% guttae ganciclovir
35 Efficacy and Safety of a Reduced Immunosuppression vs. Standard Triple Therapy in Senior Renal Transplant Recipients Not yet recruiting NCT02453867 Phase 4 Tacrolimus;mycophenolate;Steroids
36 In UTERO Treatment of Cytomegalovirus Congenital Infection With Valacyclovir Terminated NCT01037712 Phase 4 Valacyclovir (ZELITREX);Placebo
37 Ganciclovir Pharmacokinetics in Patients Undergoing Continuous Renal Replacement Therapy Terminated NCT00264368 Phase 4 intravenous (IV) ganciclovir
38 Correcting Anemia and Native Vitamin D Supplementation in Kidney Transplant Recipients Terminated NCT01817699 Phase 4
39 Prevention of Transplant Atherosclerosis With Everolimus and Anti-cytomegalovirus Therapy Unknown status NCT00966836 Phase 3 Pre-emptive strategy with valganciclovir plus everolimus;Prophylaxis with valganciclovir plus mycophenolate;Prophylaxis with valganciclovir plus everolimus;Pre-emptive mycophenolate
40 Congenital Cytomegalovirus: Efficacy of Antiviral Treatment Unknown status NCT02005822 Phase 3 Valganciclovir
41 Anti-T-Lymphocyte Globulin (ATG) in Renal Transplantation of Kidneys With a Non-Heart-Beating (NHB) Donor Unknown status NCT00733733 Phase 3 ATG Fresenius
42 Valganciclovir in Patients With CMV Retinitis and AIDS Who Cannot Take Drugs by Injection Unknown status NCT00017784 Phase 3 Valganciclovir
43 Efficacy Study of Human Cytomegalovirus (HCMV) Hyperimmune Globulin to Prevent Congenital HCMV Infection Completed NCT00881517 Phase 2, Phase 3 HCMV-specific hyperimmune globulin (Cytotect®);Isotonic solution of sodium chloride (placebo)
44 Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections Completed NCT00466817 Phase 3 Valganciclovir
45 Phase III Randomized, Controlled Study of Ganciclovir for Symptomatic Congenital Cytomegalovirus Infection Completed NCT00004278 Phase 3 ganciclovir
46 Valganciclovir to Prevent Cytomegalovirus Infection in Patients Following Donor Stem Cell Transplantation Completed NCT00016068 Phase 3 ganciclovir;valganciclovir
47 Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients Completed NCT00411645 Phase 3 maribavir
48 Maribavir Versus Oral Ganciclovir For The Prevention of Cytomegalovirus (CMV) Disease in Liver Transplant Recipients Completed NCT00497796 Phase 3 maribavir;ganciclovir
49 Artesunate in Preemptive Treatment of Human Cytomegalovirus (CMV) in Stem Cell Transplant Recipients Completed NCT00284687 Phase 3 Artesunate
50 Letermovir (MK-8228) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001) Completed NCT02137772 Phase 3 Letermovir;Placebo

Search NIH Clinical Center for Cytomegalovirus Infection

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Genetic Tests for Cytomegalovirus Infection

Anatomical Context for Cytomegalovirus Infection

MalaCards organs/tissues related to Cytomegalovirus Infection:

42
T Cells, Kidney, Liver, Bone, Lung, Heart, Testes

Publications for Cytomegalovirus Infection

Articles related to Cytomegalovirus Infection:

(show top 50) (show all 3910)
# Title Authors Year
1
Haploidentical allogeneic hematopoietic stem cell transplantation increases the risk of cytomegalovirus infection in adult patients with acute leukemia. ( 31004545 )
2019
2
Cytomegalovirus Infection May Trigger Adult-Onset Still's Disease Onset or Relapses. ( 31068953 )
2019
3
Are human Vδ2pos T cells really resistant to aging and Human Cytomegalovirus infection? ( 31072771 )
2019
4
CD28 null CD4 T-cell expansions in autoimmune disease suggest a link with cytomegalovirus infection. ( 30984377 )
2019
5
Latent Cytomegalovirus Infection in Female Mice Increases Breast Cancer Metastasis. ( 30934926 )
2019
6
Bronchopulmonary Dysplasia in Very Preterm Infants with Symptomatic Congenital Cytomegalovirus Infection: A Propensity Score-Matched Analysis. ( 30270170 )
2019
7
Perspectives of cytomegalovirus infection in ulcerative colitis. ( 31111828 )
2019
8
Polymerase chain reaction for detection of mucosal cytomegalovirus infection in patients with acute ulcerative colitis. ( 30598596 )
2019
9
Newborn screening for congenital cytomegalovirus infection…it is time. ( 31107963 )
2019
10
Results of a Targeted Screening Program for Congenital Cytomegalovirus Infection in Infants Who Fail Newborn Hearing Screening. ( 29373759 )
2019
11
Hematologic Adverse Events Associated With Prolonged Valganciclovir Treatment in Congenital Cytomegalovirus Infection. ( 29677086 )
2019
12
Is Polymerase Chain Reaction in Neonatal Dried Blood Spots Reliable for the Diagnosis of Congenital Cytomegalovirus Infection? ( 30199483 )
2019
13
Prospective Cohort Study of Congenital Cytomegalovirus Infection during Pregnancy with Fetal Growth Restriction: Serologic Analysis and Placental Pathology. ( 30413316 )
2019
14
Blood Viral Load in Symptomatic Congenital Cytomegalovirus Infection. ( 30535363 )
2019
15
Magnetic resonance imaging of cerebellar cysts in a neonate with congenital cytomegalovirus infection. ( 30612159 )
2019
16
Prevalence of Congenital Cytomegalovirus Infection and Associated Risk of In-utero HIV Acquisition in a High HIV Prevalence Setting, South Africa. ( 30615106 )
2019
17
Prediction of the Outcome of Cochlear Implantation in the Patients with Congenital Cytomegalovirus Infection based on Magnetic Resonance Imaging Characteristics. ( 30682778 )
2019
18
Histopathological analysis of placentas with congenital cytomegalovirus infection. ( 30712668 )
2019
19
Association between neuroimaging findings and neurological sequelae in patients with congenital cytomegalovirus infection. ( 30857789 )
2019
20
Direct Saliva Real-time Polymerase Chain Reaction Assay Shows Low Birth Prevalence of Congenital Cytomegalovirus Infection in Urban Western India. ( 30882739 )
2019
21
Efficacy of Valganciclovir Treatment Depends on the Severity of Hearing Dysfunction in Symptomatic Infants with Congenital Cytomegalovirus Infection. ( 30893926 )
2019
22
Hearing loss in children with congenital cytomegalovirus infection: an 11-year retrospective study based on laboratory database of a tertiary paediatric hospital. ( 30936577 )
2019
23
Erratum to: Clinical characteristics, audiological and neurodevelopmental outcomes of newborns with congenital cytomegalovirus infection. ( 30942894 )
2019
24
Severe symptomatic congenital Cytomegalovirus infection due to maternal CMV primary infection after 20 weeks of gestation. ( 31090899 )
2019
25
A new MRI severity score to predict long-term adverse neurologic outcomes in children with congenital Cytomegalovirus infection. ( 31096816 )
2019
26
Small Bowel Pyogenic Granuloma With Cytomegalovirus Infection in a Patient With Crohn's Disease (Report of a Case and Review of the Literature). ( 30587632 )
2019
27
Survey of cellular immune responses to human cytomegalovirus infection in the microenvironment of the uterine-placental interface. ( 31065796 )
2019
28
Reactivation of latent cytomegalovirus infection in patients with rheumatologic disease: a case-control study. ( 31076831 )
2019
29
Management and prevention of cytomegalovirus infection in paediatric hematopoietic stem cell transplant (HSCT) recipients: A binational survey. ( 31081265 )
2019
30
Incidence and risk factors associated with cytomegalovirus infection after thetreatment of acute rejection during the first year in kidney transplant recipients receiving preemptive therapy. ( 31081566 )
2019
31
Maternal cytomegalovirus infection and fetal impairment: uncertainty remains. ( 31090901 )
2019
32
Caspase-8-dependent control of NK- and T cell responses during cytomegalovirus infection. ( 31098689 )
2019
33
Distinct Surface Expression of Activating Receptor Ly49H Drives Differential Expansion of NK Cell Clones upon Murine Cytomegalovirus Infection. ( 31103380 )
2019
34
Cytomegalovirus Infection Drives Avidity Selection of Natural Killer Cells. ( 31103381 )
2019
35
Purpuric skin lesions possibly associated with acquired cytomegalovirus infection. ( 31106487 )
2019
36
Clinical Correlation of Cytomegalovirus Infection With CMV-specific CD8+ T-cell Immune Competence Score and Lymphocyte Subsets in Solid Organ Transplant Recipients. ( 30086091 )
2019
37
A Multicenter Case-control Study of the Effect of Acute Rejection and Cytomegalovirus Infection on Pneumocystis Pneumonia in Solid Organ Transplant Recipients. ( 30107568 )
2019
38
Definitions of Resistant and Refractory Cytomegalovirus Infection and Disease in Transplant Recipients for Use in Clinical Trials. ( 30137245 )
2019
39
Cytomegalovirus infection in day care centres: A systematic review and meta-analysis of prevalence of infection in children. ( 30306730 )
2019
40
Human Papillomavirus and Human Cytomegalovirus Infection and Association with Prognosis in Patients with Primary Glioblastoma in Pakistan. ( 30321676 )
2019
41
Cytomegalovirus Infection Incidence and Risk Factors Across Diverse Hematopoietic Cell Transplantation Platforms Using a Standardized Monitoring and Treatment Approach: A Comprehensive Evaluation from a Single Institution. ( 30342913 )
2019
42
Acute cytomegalovirus infection associated with pulmonary embolism treated successfully with rivaroxaban: case report. ( 30353451 )
2019
43
Impact of Cytomegalovirus Infection on the Outcome of Patients With Cirrhosis: A Preliminary Study. ( 30383568 )
2019
44
NFKB1 promoter polymorphism: A new predictive marker of cytomegalovirus infection after kidney transplantation. ( 30431214 )
2019
45
Restriction of Human Cytomegalovirus Infection by Galectin-9. ( 30487283 )
2019
46
Placental Cytomegalovirus Infection. ( 30500287 )
2019
47
The clinical features and mortality risk factors of cytomegalovirus infection in patients with systemic lupus erythematosus. ( 30598425 )
2019
48
Antenatal Cytomegalovirus Infection Screening Results of 32,188 Patients in a Tertiary Referral Center: A Retrospective Cohort Study. ( 30600762 )
2019
49
Cytomegalovirus infection is not a major cause of corneal graft failure in the United Kingdom. ( 30622288 )
2019
50
Severe systemic cytomegalovirus infection in an immunocompetent patient outside the intensive care unit: a case report. ( 30626344 )
2019

Variations for Cytomegalovirus Infection

Expression for Cytomegalovirus Infection

Search GEO for disease gene expression data for Cytomegalovirus Infection.

Pathways for Cytomegalovirus Infection

Pathways related to Cytomegalovirus Infection according to GeneCards Suite gene sharing:

(show top 50) (show all 146)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.04 B2M CCL2 CCL3 CCL5 CREB1 CXCL8
2
Show member pathways
13.99 CCL2 CCL3 CCL5 CREB1 CXCL8 EGFR
3
Show member pathways
13.81 CCL2 CCL3 CCL5 CREB1 CXCL8 EGFR
4
Show member pathways
13.7 CREB1 CXCL8 FAS IL1B IL6 MTOR
5
Show member pathways
13.65 CCL2 CCL3 CCL5 CREB1 CXCL8 EGFR
6
Show member pathways
13.58 B2M CREB1 EGFR HLA-A HLA-B HLA-E
7
Show member pathways
13.43 CCL2 CCL3 CCL5 CXCL8 EGFR FAS
8
Show member pathways
13.43 CCL2 CCL3 CCL5 CREB1 CXCL8 EGFR
9
Show member pathways
13.35 CREB1 EGFR IL1B MTOR NFKB1 SP1
10
Show member pathways
13.23 CCL2 CCL3 CCL5 CXCL8 FAS IL1B
11
Show member pathways
13.11 CCL2 CCL5 EGFR FAS IL6 MTOR
12
Show member pathways
13.04 CREB1 EGFR FAS NFKB1 TNF TNFRSF1A
13
Show member pathways
13.01 CCL2 CCL3 CCL5 CXCL8 FAS NFKB1
14 13 CXCL8 EGFR FAS IL6 MTOR NFKB1
15
Show member pathways
12.98 CREB1 EGFR FAS HLA-A HLA-B HLA-E
16
Show member pathways
12.97 B2M CCL2 CCL3 CCL5 CXCL8 EGFR
17
Show member pathways
12.93 B2M CCL2 CCL3 CCL5 CREB1 CXCL8
18
Show member pathways
12.92 CREB1 IL6 MTOR NFKB1 TNF TNFRSF1A
19 12.91 EGFR FAS IL1B NFKB1 TNF TNFRSF1A
20
Show member pathways
12.9 CCL5 CXCL8 IL1B IL6 NFKB1 TNF
21
Show member pathways
12.87 B2M CREB1 CXCL8 FAS HLA-A HLA-B
22
Show member pathways
12.86 CREB1 EGFR FAS IL1B NFKB1 SP1
23
Show member pathways
12.85 EGFR IL1B IL6 NFKB1 TNF TNFRSF1A
24
Show member pathways
12.79 EGFR IL1B MTOR NFKB1 SP1
25
Show member pathways
12.76 CREB1 FAS IL1B NFKB1 TNF TNFRSF1A
26
Show member pathways
12.75 CCL2 EGFR IL1B IL6 NFKB1 TNF
27
Show member pathways
12.73 CREB1 FAS IL1B IL6 NFKB1 TNF
28
Show member pathways
12.72 IL1B IL6 MTOR NFKB1 TNF
29 12.69 B2M CCL2 CCL5 FAS IL1B NFKB1
30
Show member pathways
12.68 FAS HLA-A HLA-B HLA-E HLA-G TNF
31
Show member pathways
12.67 B2M HLA-A HLA-B HLA-E HLA-G
32
Show member pathways
12.66 CREB1 IL1B IL6 NFKB1 SP1
33
Show member pathways
12.63 CREB1 FAS NFKB1 TNF TNFRSF1A
34
Show member pathways
12.62 CREB1 IL1B MTOR NFKB1 SP1
35
Show member pathways
12.61 B2M HLA-A HLA-B HLA-E HLA-G
36 12.55 EGFR HLA-A HLA-B HLA-E HLA-G
37
Show member pathways
12.54 EGFR IL1B MTOR NFKB1
38
Show member pathways
12.51 CCL2 CCL5 IL1B IL6 NFKB1 TNF
39
Show member pathways
12.51 CCL2 CXCL8 IL1B IL6 NFKB1 SP1
40
Show member pathways
12.5 CXCL8 EGFR MTOR SP1
41
Show member pathways
12.5 CCL2 CREB1 NFKB1 SP1
42
Show member pathways
12.49 CREB1 CXCL8 IL1B IL6 NFKB1 TNF
43 12.47 CREB1 HLA-A HLA-B HLA-E HLA-G NFKB1
44 12.45 CREB1 HLA-A HLA-B HLA-E HLA-G IL6
45
Show member pathways
12.44 CREB1 MTOR NFKB1 SP1
46
Show member pathways
12.44 FAS NFKB1 TNF TNFRSF1A
47
Show member pathways
12.41 CREB1 IL6 MTOR NFKB1
48 12.41 EGFR FAS MTOR TNF
49 12.41 CREB1 IL1B IL6 NFKB1 TNF TNFRSF1A
50
Show member pathways
12.4 CXCL8 EGFR HLA-A HLA-B HLA-E HLA-G

GO Terms for Cytomegalovirus Infection

Cellular components related to Cytomegalovirus Infection according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 membrane raft GO:0045121 9.8 EGFR FAS TNF TNFRSF1A
2 recycling endosome membrane GO:0055038 9.77 B2M HLA-A HLA-B HLA-E HLA-G
3 phagocytic vesicle membrane GO:0030670 9.72 B2M HLA-A HLA-B HLA-E HLA-G
4 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.71 HLA-A HLA-B HLA-E HLA-G
5 ER to Golgi transport vesicle membrane GO:0012507 9.55 B2M HLA-A HLA-B HLA-E HLA-G
6 early endosome membrane GO:0031901 9.43 B2M EGFR HLA-A HLA-B HLA-E HLA-G
7 MHC class I protein complex GO:0042612 9.02 B2M HLA-A HLA-B HLA-E HLA-G
8 extracellular space GO:0005615 10.18 B2M CCL2 CCL3 CCL5 CXCL8 EGFR
9 extracellular region GO:0005576 10.07 B2M CCL2 CCL3 CCL5 CXCL8 EGFR
10 cell surface GO:0009986 10.06 B2M EGFR FAS HLA-A HLA-B HLA-E
11 Golgi membrane GO:0000139 10.03 B2M EGFR HLA-A HLA-B HLA-E HLA-G

Biological processes related to Cytomegalovirus Infection according to GeneCards Suite gene sharing:

(show top 50) (show all 77)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.99 IL1B IL6 NFKB1 TNF
2 neutrophil chemotaxis GO:0030593 9.97 CCL2 CCL3 CCL5 CXCL8 IL1B
3 cellular response to interleukin-1 GO:0071347 9.97 CCL2 CCL3 CCL5 CXCL8 NFKB1
4 positive regulation of inflammatory response GO:0050729 9.96 CCL3 EGFR TNF TNFRSF1A
5 cellular response to mechanical stimulus GO:0071260 9.96 EGFR FAS IL1B NFKB1 TNFRSF1A
6 chemokine-mediated signaling pathway GO:0070098 9.95 CCL2 CCL3 CCL5 CXCL8
7 type I interferon signaling pathway GO:0060337 9.94 HLA-A HLA-B HLA-E HLA-G
8 cell chemotaxis GO:0060326 9.93 CCL2 CCL3 CCL5
9 cellular response to organic cyclic compound GO:0071407 9.93 CCL2 CCL3 CCL5 IL1B TNF
10 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.92 EGFR IL6 TNF
11 monocyte chemotaxis GO:0002548 9.92 CCL2 CCL3 CCL5 IL6
12 interferon-gamma-mediated signaling pathway GO:0060333 9.92 B2M HLA-A HLA-B HLA-E HLA-G
13 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.91 CCL5 IL6 TNFRSF1A
14 regulation of insulin secretion GO:0050796 9.91 CCL5 IL1B TNF
15 positive regulation of T cell proliferation GO:0042102 9.9 CCL5 IL1B IL6
16 positive regulation of interleukin-6 production GO:0032755 9.9 IL1B IL6 TNF
17 humoral immune response GO:0006959 9.89 CCL2 IL6 TNF
18 cellular response to amino acid stimulus GO:0071230 9.89 EGFR MTOR TNF
19 positive regulation of smooth muscle cell proliferation GO:0048661 9.89 CCL5 EGFR IL6 MTOR TNF
20 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.88 EGFR IL1B TNF
21 visual learning GO:0008542 9.88 CREB1 MTOR RAG1
22 protein kinase B signaling GO:0043491 9.88 CCL2 CCL3 CCL5 IL1B TNF
23 antigen processing and presentation GO:0019882 9.87 HLA-A HLA-B HLA-E
24 positive regulation of nitric oxide biosynthetic process GO:0045429 9.87 IL1B MTOR TNF
25 lymphocyte chemotaxis GO:0048247 9.86 CCL2 CCL3 CCL5
26 cellular response to fibroblast growth factor stimulus GO:0044344 9.85 CCL2 CCL5 CXCL8
27 negative regulation of neurogenesis GO:0050768 9.85 IL1B IL6 TNF
28 lipopolysaccharide-mediated signaling pathway GO:0031663 9.85 CCL2 CCL3 CCL5 IL1B TNF
29 eosinophil chemotaxis GO:0048245 9.84 CCL2 CCL3 CCL5
30 macrophage chemotaxis GO:0048246 9.81 CCL2 CCL3 CCL5
31 positive regulation of glial cell proliferation GO:0060252 9.81 IL1B IL6 MTOR TNF
32 inflammatory response GO:0006954 9.81 CCL2 CCL3 CCL5 CXCL8 IL1B IL6
33 antigen processing and presentation of peptide antigen via MHC class I GO:0002474 9.8 B2M HLA-A HLA-B HLA-E HLA-G
34 regulation of establishment of endothelial barrier GO:1903140 9.78 IL1B TNF TNFRSF1A
35 positive regulation of neuroinflammatory response GO:0150078 9.77 IL1B IL6 TNF
36 protection from natural killer cell mediated cytotoxicity GO:0042270 9.76 HLA-A HLA-B HLA-E
37 negative regulation by host of viral transcription GO:0043922 9.75 CCL3 CCL5
38 PERK-mediated unfolded protein response GO:0036499 9.75 CCL2 CXCL8
39 positive regulation of immunoglobulin secretion GO:0051024 9.75 HLA-E IL6
40 response to molecule of bacterial origin GO:0002237 9.74 B2M CXCL8
41 neutrophil activation GO:0042119 9.74 CCL5 CXCL8
42 astrocyte activation GO:0048143 9.74 EGFR TNF
43 negative regulation of lipid storage GO:0010888 9.74 IL6 TNF
44 negative regulation of T cell apoptotic process GO:0070233 9.74 CCL5 RAG1
45 positive regulation of ceramide biosynthetic process GO:2000304 9.73 TNF TNFRSF1A
46 response to glucocorticoid GO:0051384 9.73 IL6 TNF
47 cellular response to nicotine GO:0071316 9.73 NFKB1 TNF
48 death-inducing signaling complex assembly GO:0071550 9.73 TNF TNFRSF1A
49 positive regulation of chemokine biosynthetic process GO:0045080 9.72 IL1B TNF
50 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent GO:0002479 9.72 B2M HLA-A HLA-B HLA-E HLA-G

Molecular functions related to Cytomegalovirus Infection according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.85 CCL2 EGFR HLA-A HLA-B HLA-E HLA-G
2 transcription regulatory region DNA binding GO:0044212 9.81 CREB1 NFKB1 SP1 TNF
3 chemokine activity GO:0008009 9.62 CCL2 CCL3 CCL5 CXCL8
4 CCR chemokine receptor binding GO:0048020 9.58 CCL2 CCL3 CCL5
5 peptide antigen binding GO:0042605 9.56 HLA-A HLA-B HLA-E HLA-G
6 cytokine activity GO:0005125 9.5 CCL2 CCL3 CCL5 CXCL8 IL1B IL6
7 beta-2-microglobulin binding GO:0030881 9.49 HLA-A HLA-E
8 CCR5 chemokine receptor binding GO:0031730 9.48 CCL3 CCL5
9 phospholipase activator activity GO:0016004 9.46 CCL3 CCL5
10 CCR1 chemokine receptor binding GO:0031726 9.43 CCL3 CCL5
11 identical protein binding GO:0042802 9.36 B2M CCL3 CCL5 CREB1 EGFR FAS
12 protein binding GO:0005515 10.16 B2M CCL2 CCL3 CCL5 CREB1 CXCL8

Sources for Cytomegalovirus Infection

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....